Combinostics to Showcase Comprehensive Solutions for the Entire Patient Care Pathway of Neurological Disorders at RSNA

Company will introduce new cPET™ solution for automated FDG and amyloid PET quantification to its platform to go beyond neurological image quantification

Tampere, Finland, November 23, 2022Combinostics, the only company providing a complete imaging and decision support solution spanning the entire patient care pathway for the early detection, diagnosis, and ongoing management of major neurological disorders, today announced that it will showcase new and existing capabilities of their cloud-based platform, including the Dementia Differential Analysis report, clinically focused reports, new cPET application* for automated FDG and amyloid PET quantification, and new cARIA™ application* for the detection of side effects, at the Radiological Society of North America (RSNA) 2022 Annual Meeting.
“RSNA is an exciting event for us, and we are looking forward to returning to show our continued growth throughout 2022 and demonstrating cMRI™, cPET, cARIA, and the Dementia Differential Analysis report.” said Richard Hausmann, CEO of Combinostics. “These are the only imaging solutions that go beyond neurological image quantification, providing radiologists with a single platform to support end-to-end workflows so they can more confidently detect brain abnormalities and provide additional services and diagnostic support for their neurology referrers.”

New cPET application

The new cPET application provides nuclear medicine physicians with precise quantification of FDG and amyloid PET scans, with comparison to tracer-specific normative data. cPET integrates segmentations from the company’s cMRI application when available to provide a more complete quantification of all brain regions including small structures such as the hippocampus.
“cPET complements our existing solutions,” said Lennart Thurfjell, COO of Combinostics. “By continuing to innovate the use of AI, we are providing additional objective data to holistically manage patients with neurological disorders.”

New cARIA application

With the new cARIA application, radiologists and their neurology referrers can access support for the detection and monitoring of side effects related to new disease-modifying treatments for Alzheimer’s disease.

New cMRI clinically focused reports and unique Dementia Differential Analysis report

Combinostics’ new clinically focused cMRI reports for dementia, multiple sclerosis, traumatic brain injury, and epilepsy present clinically relevant imaging information for each of the four conditions. Annotated images, quality control of MRI inputs, percentile graphs, and color coding of values that fall outside of the normal reference range provide transparency into our underlying processes. The reports also provide a quick and easy method of verifying and consolidating the results for each patient.
The Dementia Differential Analysis report offers true differential diagnostic support for dementias using MRI data only and can support radiologists in providing additional value for referring neurologists. Using proprietary analyses and biomarkers, the report visualizes the quantification and evaluation of patient MRI data against the distributions of key dementia-specific imaging biomarkers and reference data from patients with a confirmed neurodegenerative disease, including frontotemporal dementia, Alzheimer’s disease, and vascular dementia.

Additional recent news

The new product developments follow news that Fountain Health will provide full coverage of cMRI and cDSI, the first health insurance company to do so. Combinostics also recently announced the expansion of their leadership team, adding two experienced executives: Dr. Erik Post as Group Chief Financial Officer (CFO), and Dr. Hans-Peter Huber as Vice President of European Sales.

At RSNA

Hausmann will be presenting “MRI Only Differentiation of Dementias: AI-enabled Diagnostic Trend to Enable Differentiation of Dementias with Imaging Alone” on November 28 in the AI Theatre at RSNA. Combinostics’ leadership and sales team will also be demoing the newest capabilities of their solutions, including the new reports and cPET, which will be available for clinical use in the United States in early 2023, at booth 3938 in the AI Showcase. Schedule an in-person or virtual meeting.

*Currently under development and not yet cleared for clinical use

About Combinostics

Combinostics’ AI-powered cNeuro suite of products helps clinicians make a difference in the lives of patients with neurological disorders. By quantifying brain images and integrating patient data from multiple sources with insights from previous patients, the company’s unique software tools provide radiologists and clinicians the support they need for confident, evidence-based diagnostic and management decisions. The company was founded in 2014 and is headquartered in Tampere, Finland. For more information, please visit www.combinostics.com.

Recent News & Events